Arcutis Biotherapeutics, Inc. (ARQT) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
ARQT EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ARQT Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 90.2% | -3.3% | -4.3% |
| 2024 | 90.3% | -65.3% | -71.3% |
| 2023 | 91.6% | -404.5% | -439.8% |
| 2022 | 79.5% | -8183.0% | -8449.8% |
| 2021 | - | - | - |
Download Data
Export ARQT earnings history in CSV or JSON format
Free sign-in required to download data
Arcutis Biotherapeutics, Inc. (ARQT) Earnings Overview
As of May 8, 2026, Arcutis Biotherapeutics, Inc. (ARQT) reported trailing twelve-month net income of -$2M, reflecting +88.8% year-over-year growth. The company earned $-0.02 per diluted share over the past four quarters, with a net profit margin of -4.3%.
Looking at the long-term picture, ARQT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2017.
Arcutis Biotherapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including DERM (-$9M net income, -26.1% margin), NVCR (-$173M net income, -20.8% margin), PRGO (-$1.82B net income, -33.5% margin), ARQT has outperformed on profitability metrics. Compare ARQT vs DERM →
ARQT Earnings vs Peers
Earnings metrics vs comparable public companies
ARQT Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$16M | +88.5% | -$12M | $-0.13 | -4.3% | -3.3% |
| 2024 | -$140M | +46.6% | -$128M | $-1.16 | -71.3% | -65.3% |
| 2023 | -$262M | +15.8% | -$241M | $-3.78 | -439.8% | -404.5% |
| 2022 | -$311M | -50.9% | -$302M | $-5.66 | -8449.8% | -8183.0% |
| 2021 | -$206M | -52.1% | -$207M | $-4.17 | - | - |
| 2020 | -$136M | -223.1% | -$137M | $-3.80 | - | - |
| 2019 | -$42M | -118.1% | -$43M | $-1.10 | - | - |
| 2018 | -$19M | -286.8% | -$20M | $-0.53 | - | - |
| 2017 | -$5M | - | -$4M | $-4.71 | - | - |
See ARQT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARQT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARQT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonARQT — Frequently Asked Questions
Quick answers to the most common questions about buying ARQT stock.
Is ARQT growing earnings?
ARQT EPS is $-0.02, with earnings growth accelerating to +88.8%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-2M.
What are ARQT's profit margins?
Arcutis Biotherapeutics, Inc. net margin is -4.3%, with operating margin at -3.3%. Below-average margins reflect competitive or cost pressures.
How consistent are ARQT's earnings?
ARQT earnings data spans 2017-2025. The accelerating earnings trend is +88.8% YoY. Historical data enables comparison across business cycles.